2. Academic Validation
  3. Discovery of a Potent and Selective Covalent p300/CBP Inhibitor

Discovery of a Potent and Selective Covalent p300/CBP Inhibitor

  • ACS Med Chem Lett. 2021 Apr 5;12(5):726-731. doi: 10.1021/acsmedchemlett.0c00654.
Anthony Mastracchio 1,  Chunqiu Lai 1,  Enrico Digiammarino 1,  Damien B Ready 1,  Loren M Lasko 1,  Kenneth D Bromberg 1,  William J McClellan 1,  Debra Montgomery 1,  Vlasios Manaves 1,  Bailin Shaw 1,  Mikkel Algire 1,  Melanie J Patterson 1,  Chaohong C Sun 1,  Saul Rosenberg 1,  Albert Lai 1,  Michael R Michaelides 1
Affiliations

Affiliation

  • 1 AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
PMID: 34055218 DOI: 10.1021/acsmedchemlett.0c00654
Abstract

Aberrant gene activation driven by the histone acetyltransferases p300 and CREB binding protein (CBP) has been linked to several diseases, including cancers. Because of this, many efforts have been aimed toward the targeting of the closely related paralogues, p300 and CBP, but these endeavors have been exclusively directed toward noncovalent inhibitors. X-ray crystallography of A-485 revealed that both p300 and CBP possess a cysteine (C1450) near the active site, thus rendering covalent inhibition an attractive chemical approach. Herein we report the development of compound 2, an acrylamide-based inhibitor of p300/CBP that forms a covalent adduct with C1450. We demonstrated using mass spectrometry that compound 2 selectively targets C1450, and we also validated covalent binding using kinetics experiments and cellular washout studies. The discovery of covalent inhibitor 2 gives us a unique tool for the study of p300/CBP biology.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z